| 1 |
Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection |
|
| | Xiaofeng Lu, Xianlu Zeng, Miaohong Chen, Zixin Fan, Lei Zheng, Ya Tian, Shaochong Zhang, Ji C. He, Guoming Zhang | | | Graefe's Archive for Clinical and Experimental Ophthalmology. 2022; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease |
|
| | Marcel N Menke,Carsten Framme,Mathias Nelle,Markus R Berger,Veit Sturm,Sebastian Wolf | | | BMC Ophthalmology. 2015; 15(1) | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Bevacizumab (Avastin) for the Treatment of Ocular Disease |
|
| | Gunther, J.B., Altaweel, M.M. | | | Survey of Ophthalmology. 2009; 54(3): 372-400 | | | [Pubmed] [Google Scholar] | | | 4 |
Bevacizumab (Avastin) for the Treatment of Ocular Disease |
|
| | Jonathan B. Gunther,Michael M. Altaweel | | | Survey of Ophthalmology. 2009; 54(3): 372 | | | [Pubmed] [Google Scholar] [DOI] | |
|
